Working… Menu
Trial record 79 of 163 for:    ISOTRETINOIN

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01916187
Recruitment Status : Withdrawn (drug company withdrww support following a re-examination of the benefit-risk assessment for the investigational use of imetelstat in this population)
First Posted : August 5, 2013
Last Update Posted : February 10, 2014
Geron Corporation
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group )

Brief Summary:
The purpose of this study is to determine the best dose of imetelstat when given alone for patients with neuroblastoma and also when given in combination with 13-cis-retinoic acid.

Condition or disease Intervention/treatment Phase
Neuroblastoma Drug: Imetelstat Phase 1

Detailed Description:
This research is being done because imetelstat has been shown to slow the growth of tumours in animals and may also be doing so in adults, but we are not sure if it can also slow tumour growth in children and offer better results than standard treatment. Laboratory studies suggest imetelstat may increase the activity of 13-cis-retinoic acid, which is used to treat neuroblastoma, although this is not yet proven in patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Imetelstat Given Intravenously on Day 1 and 8 of a 21 Day Schedule Alone and With Standard 13-Cis-Retinoic Acid in Children With Recurrent and/or Refractory Neuroblastoma
Study Start Date : July 2013
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma

Arm Intervention/treatment
Experimental: Imetelstat
285 mg/m2/dose, IV, for 2 hours. Days 1 and 8 every three weeks.
Drug: Imetelstat

Primary Outcome Measures :
  1. Effectiveness of Imetelstat in pediatric dose [ Time Frame: 24 month ]
    Response and progression will be evaluated in this study using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee in patients with relapsed and/or refractory neuroblastoma, to confirm the feasibility of administering imetelstat given at the recommended pediatric dose as determined in the Children's Oncology Group Study ADVL1112 (a phase I study of imetelstat, a telomerase inhibitor, in children with recurrent or refractory solid tumours and lymphoma), alone and in combination with 13-cis-retinoic acid.

Secondary Outcome Measures :
  1. Impact of imetelstat on hematopoietic stem cells and neuroblastoma tumour cells. [ Time Frame: 24 months ]
    Bone marrow aspirates, biopsies and blood samples for CC assay: at baseline, end of cycles 1 and 2 then end of every other cycle will be assessed in patients with relapsed and/or refractory neuroblastoma to assess the impact of imetelstat on hematopoietic stem cells and neuroblastoma tumour initiating cells.

  2. Changes in plasma C-circles [ Time Frame: 24 months ]

    In patients with relapsed and/or refractory neuroblastoma to evaluate:

    • The correlation of tumour and plasma C-circles.
    • The role of plasma C-circles as a tumour biomarker for alternative lengthening of telomeres (ALT).
    • Changes in plasma C-circles induced by treatment with imetelstat.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological verification of neuroblastoma at either original diagnosis or relapse.
  • Patients must have recurrent or refractory neuroblastoma with either measurable or evaluable disease (defined by a positive nuclear scan such as bone scan or metaiodobenzylguanidine (MIBG) scan). If a lesion is isolated and /or previously irradiated and stable, a proven positive biopsy will be required to be eligible.
  • Current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
  • Must have recovered from the acute effects of prior chemotherapy, immunotherapy or radiotherapy prior to study entry as follows:

    • At least 3 weeks from completion of last active cancer therapy and recovered from toxic effects of that therapy to ≤ grade 1.
    • At least 6 weeks post hematopoietic stem cell rescue following myeloablative therapy.
    • At least 3 months must have elapsed if prior total body irradiation, craniospinal XRT or if ≥ 50% radiation of pelvis.
    • At least 6 weeks must have elapsed if other substantial bone marrow irradiation.
    • At least 6 weeks from prior MIBG therapy.
  • Age >18 months and ≤18 years at the time of study entry.
  • Performance Status:

Patients ≤10 years: Lansky ≥50 Patients >10 years: Karnofsky ≥60% - Laboratory Requirements: (must be done within 7 days prior to registration)

Adequate Bone Marrow Function, defined as:

  • Absolute neutrophil count (ANC) ≥1.0 x 10^9/L
  • Platelets ≥100 x 10^9/L (transfusion independent defined as not receiving platelet transfusions within 7 days prior to registration)
  • Hemoglobin ≥80 g/L (may receive RBC transfusions) Patients with known bone marrow metastatic disease will be eligible for the study and may receive transfusions, provided ≤25% of bone marrow is involved, and provided they are not known to be refractory to red cell or platelet transfusions.

Patients will be eligible as long as blood count criteria are met. If patients then experience prolonged myelosuppression, bone marrow examination can be requested to determine if the low blood counts are due to malignant infiltration of the marrow or to therapy induced hypoplasia/aplasia.

Adequate Renal And Cardiac Function, defined as:

  • Serum creatinine ≤1.5 x upper limit of normal for age or
  • Measured GFR ≥70 mL/min/1.73 m2

Adequate Liver Function, defined as:

  • AST and ALT ≤2.5 x upper limit normal for age
  • Total bilirubin ≤1.5 x upper limit normal for age
  • Serum albumin ≥ 20

Adequate Coagulation Function, defined as:

• PTT <1.2 x upper limit normal

  • Patient or guardian consent must be obtained on all patients according to local Institutional and/or University Human Experimentation Committee requirements. Children > 8 years old whose parent or guardian has signed consent on their behalf may also sign assent if desired. It will be the responsibility of the local participating investigators to obtain the necessary local clearance, and to indicate in writing to the NCIC CTG Study Coordinator that such clearance has been obtained, before the trial can commence in that centre.
  • Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits (for example: two hour's driving distance) placed on patients being considered for this trial.
  • Protocol treatment is to begin within 5 working days of patient registration.

Exclusion Criteria:

  • Patients with >25% bone marrow involvement will not be enrolled.
  • Patients must be able to take oral medication and have no gastrointestinal abnormalities (e.g. bowel obstruction or previous gastric resection) which would lead to inadequate absorption of 13-cisretinoic acid.
  • Known HIV, hepatitis B or hepatitis C infections.
  • Imetelstat animal and in vitro studies suggest it is not genotoxic or teratogenic. However, 13-cis-retinoic acid is known to be teratogenic. Pregnancy tests must be obtained in girls who are post menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two reliable contraceptive methods. Pregnant or breast-feeding females will not be entered on this study due to the potential fetal and teratogenic adverse effects.
  • Concurrent Medications:

    • Patients receiving other investigational agents will not be enrolled.
    • Patient receiving other anti-cancer agents will not be enrolled.
    • Patients with CNS metastasis will need to submit to a baseline MRI obtained within 21 days prior to registration. Patients with evidence of current or prior CNS hemorrhage will be excluded. Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study will not be enrolled.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01916187

Layout table for location information
Canada, Quebec
CHU Sainte-Justine
Montreal, Quebec, Canada, H3T 1C5
Sponsors and Collaborators
NCIC Clinical Trials Group
Geron Corporation
Layout table for investigator information
Study Chair: Victor Lewis Alberta Children's Hospital, Southern Alberta Children's Cancer Program, AB Canada

Layout table for additonal information
Responsible Party: NCIC Clinical Trials Group Identifier: NCT01916187     History of Changes
Other Study ID Numbers: I212
First Posted: August 5, 2013    Key Record Dates
Last Update Posted: February 10, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Motesanib diphosphate
Antineoplastic Agents
Keratolytic Agents
Dermatologic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs